Form 4: Disc Medicine CFO Executes Planned Stock Sale

Chief Financial Officer Jean M. Franchi sold 6,657 shares of Disc Medicine, Inc. common stock via a Rule 10b5-1 plan.

Summary

• CFO Jean M. Franchi sold a total of 6,657 shares of common stock on April 13 and April 14, 2026.
• The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on September 25, 2025.
• Following these transactions, the CFO retains beneficial ownership of 64,333 shares of common stock.
• The shares were sold at weighted average prices of $69.00 and $69.2399 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a standard liquidity event for an executive.

Positives

• The transactions were conducted under a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• Continued selling by key executives may be perceived negatively by retail investors, potentially impacting short-term sentiment.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine corporate governance events and generally do not signal a change in the company's fundamental outlook or operational health.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage personal liquidity while maintaining compliance with SEC regulations.

Stakeholder Impact

• Minimal impact expected as the sale was executed via a pre-planned trading program.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Disc Medicine, IRON, Insider Trading, Form 4, CFO, Equity Sale